Sodium Butyrate 50%70%90% Microcapsule Sodium Butyrate_Xian Sgonek Biological Technology Co.,Ltd

Sodium Butyrate 50%70%90% Microcapsule Sodium Butyrate

1.CAS NO: 112809-51-5

2.letrozole Content: 99%

3.Molecular Formula: C17H11N5

4. Molecular Weight: 285.31

5. Appearance white or off-white powder

6. Melting point 181-183 ° C

Letrozole is an oral non-steroidal inhibitor for the treatment of hormonally-responsive breast cancer after surgery. letrozole prevents the aromatase from producing estrogens by competitive, reversible binding to the heme of its cytochrome p450 unit, the action is specific,and letrozol does not reduce production of mineralo-or corticosteroids.

Letrozole is a new generation aromatase inhibitor, is a synthetic derivative of benzyl triazole, letrozole by inhibiting aromatase, estrogen levels drop, thereby eliminating the stimulating effect of estrogen on tumor growth. Chemotherapy and radiotherapy for breast cancer.

Tests	Specifications	Results
Appearance	White or off-white crystaline powder	White Crystalline powder
Solubility	Soluble in Chloroform; Soluble in ethanol when heated	Conform
ldentification	(1)Maximum absorption in wavelength of 240 nm Minimum absorption in wavelength of 215 nm	Conform Conform
ldentification	(2)Infrared spectrum should be in accordance the dominant peak of contrast	In accordance with the dominant peak of contrast
Melting points	182°C-184°C	182°C
Related substances	≤0.5%	0.3%
Single impurity	≤0.3%	0.2%
Loss on drying	≤1.0%	0.8%
[Assay]C17H11N5 (On anhydrous basis)	≥98.0%	99.2%
Conclusion	Conforms Specifications of Enterprise Standard.

1. Letrozole has been used for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation. A Canadian study presented at the American Society of Reproductive Medicine 2005 Conference suggested that letrozole may increase the risk of birth defects.[citation needed] A more detailed ovulation induction follow-up study found that letrozole, compared with a control group of clomiphene, had significantly lower congenital malformations and chromosomal abnormalities at an overall rate of 2.4% (1.2% major malformations) compared with clomiphene 4.8% (3.0% major malformations). Despite this, India banned the usage of letrozole in 2011, citing potential risks to infants.In 2012, an Indian parliamentary committee said that the drug controller office colluded with letrozole's makers to approve the drug for infertility in India and also stated that letrozole's use for infertility was illegal worldwide; however, such off-label uses are legal in many countries such as the US and UK.

The anti-estrogen action of letrozole has been shown to be useful in pretreatment for termination of pregnancy, in combination with misoprostol. It can be used in place of mifepristone, which is expensive and unavailable in many countries.
2. Letrozole is sometimes used as a treatment for gynecomastia, although it is probably most effective at this if caught in an early stage (such as in users of anabolic steroids).
3. Letrozole has also been shown to delay the fusing of the growth plates in mice.When used in combination with growth hormone, letrozole has been shown effective in one adolescent boy with a short stature.

Product Name:	Letrozole	Cas No.:	112809-51-5
Molecular Formula:	C17H11N5	Purity:	99%min
Brand Name:	SGONEK	Certification:	ISO FDA SG COA MSDS

Sodium Butyrate 50%70%90% Microcapsule Sodium Butyrate

Sodium Butyrate 50%70%90% Microcapsule Sodium Butyrate

Contact Us

Product Category

contact us

Name：
E-mail：
Message：